IN2012CN10925A - - Google Patents

Info

Publication number
IN2012CN10925A
IN2012CN10925A IN10925CHN2012A IN2012CN10925A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A IN 10925CHN2012 A IN10925CHN2012 A IN 10925CHN2012A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A
Authority
IN
India
Prior art keywords
trifluoromethyl
phenyl
ethyl
amino
methyl
Prior art date
Application number
Inventor
Tadaaki Ohgiya
Takeshi Murakami
Katsutoshi Miyosawa
Kimiyuki Shibuya
Koichi Yamazaki
Taichi Kusakabe
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of IN2012CN10925A publication Critical patent/IN2012CN10925A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A substantially optically pure (S) trans {4 [({2 [({1 [3 5 bis(trifluoromethyl) phenyl] ethyl}{5 [2 (methylsulfonyl) ethoxy] pyrimidine 2 yl} amino) methyl] 4 (trifluoromethyl) phenyl} (ethyl) amino) methyl] cyclohexyl} aceitic acid having the effect of reducing the amount of PCSK9 proteins and increasing the amount of LDL receptors or a salt thereof or a solvate thereof.
IN10925CHN2012 2010-06-04 2011-06-03 IN2012CN10925A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010128585 2010-06-04
JP2010218299 2010-09-29
PCT/JP2011/062751 WO2011152508A1 (en) 2010-06-04 2011-06-03 Optically active dibenzylamine derivative, and manufacturing method for same

Publications (1)

Publication Number Publication Date
IN2012CN10925A true IN2012CN10925A (en) 2015-04-24

Family

ID=45066863

Family Applications (1)

Application Number Title Priority Date Filing Date
IN10925CHN2012 IN2012CN10925A (en) 2010-06-04 2011-06-03

Country Status (18)

Country Link
US (1) US8906895B2 (en)
EP (1) EP2578574B1 (en)
JP (1) JP5555320B2 (en)
KR (2) KR20130111512A (en)
CN (2) CN102933559B (en)
AU (1) AU2011259929B2 (en)
BR (1) BR112012030787A2 (en)
CA (1) CA2801417C (en)
EA (1) EA024241B1 (en)
ES (1) ES2581557T3 (en)
HK (1) HK1179959A1 (en)
IL (1) IL223377A (en)
IN (1) IN2012CN10925A (en)
MX (1) MX338024B (en)
PT (1) PT2578574E (en)
TW (1) TWI492749B (en)
WO (1) WO2011152508A1 (en)
ZA (1) ZA201209372B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046681A1 (en) * 2010-10-04 2012-04-12 興和株式会社 Agent for inhibiting expression of lipid metabolism related mrna
US9272966B2 (en) 2010-07-22 2016-03-01 Kowa Company, Ltd. Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane
US20140303198A1 (en) * 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
WO2013081087A1 (en) * 2011-12-02 2013-06-06 興和株式会社 Method for preparing optically active compound
JPWO2013137371A1 (en) * 2012-03-15 2015-08-03 興和株式会社 Novel pyrimidine compounds and pharmaceuticals containing them
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
WO2014170786A1 (en) 2013-04-17 2014-10-23 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN105246877A (en) * 2013-05-31 2016-01-13 兴和株式会社 Novel form of pyrimidinic compound having dibenzylamine structure
JP2017528448A (en) * 2014-08-21 2017-09-28 エスアールエックス カーディオ，エル エル シー Compositions of small molecules as binding ligands and methods of use thereof for the modulation of the protein activity of the proprotein convertase subtilisin / kexin type 9 (PCSK9)
TWI691331B (en) 2014-09-26 2020-04-21 日商興和股份有限公司 A treating agent for dyslipidemia
WO2016084950A1 (en) * 2014-11-28 2016-06-02 興和株式会社 Pharmaceutical composition
KR20170087880A (en) * 2014-11-28 2017-07-31 코와 가부시키가이샤 Medicine
JP2019131472A (en) * 2016-05-31 2019-08-08 興和株式会社 Pharmaceutical composition
CN113574055A (en) * 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 PCSK9 inhibitors and methods of use thereof
BR112021013924A2 (en) 2019-01-18 2021-09-21 Astrazeneca Ab PCSK9 INHIBITORS AND METHODS OF USING THEM

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189208A (en) * 1991-07-01 1993-02-23 Ethyl Corporation Ibuprofen resolution
JP5244095B2 (en) 2007-04-13 2013-07-24 興和株式会社 Pyrimidine compounds having a novel dibenzylamine structure and pharmaceuticals containing the same
WO2009143633A1 (en) 2008-05-30 2009-12-03 Institut De Recherches Cliniques De Montreal Pcsk9 inhibitors and methods of use thereof
WO2012046681A1 (en) 2010-10-04 2012-04-12 興和株式会社 Agent for inhibiting expression of lipid metabolism related mrna

Also Published As

Publication number Publication date
CA2801417A1 (en) 2011-12-08
AU2011259929A1 (en) 2013-01-17
EP2578574A4 (en) 2013-12-04
CN104529910B (en) 2017-05-10
EA024241B1 (en) 2016-08-31
TWI492749B (en) 2015-07-21
ES2581557T3 (en) 2016-09-06
AU2011259929B2 (en) 2014-07-31
JP5555320B2 (en) 2014-07-23
MX338024B (en) 2016-03-31
EP2578574A1 (en) 2013-04-10
CA2801417C (en) 2017-07-11
HK1179959A1 (en) 2013-10-11
CN102933559A (en) 2013-02-13
CN104529910A (en) 2015-04-22
US8906895B2 (en) 2014-12-09
KR20170078865A (en) 2017-07-07
BR112012030787A2 (en) 2020-09-01
ZA201209372B (en) 2014-02-26
JPWO2011152508A1 (en) 2013-08-01
IL223377A0 (en) 2013-03-05
EP2578574B1 (en) 2016-04-27
PT2578574E (en) 2016-06-17
WO2011152508A1 (en) 2011-12-08
MX2012014149A (en) 2013-02-27
US20130225814A1 (en) 2013-08-29
TW201208688A (en) 2012-03-01
EA201291447A1 (en) 2013-05-30
KR20130111512A (en) 2013-10-10
IL223377A (en) 2016-12-29
CN102933559B (en) 2016-01-27

Similar Documents

Publication Publication Date Title
IN2012CN10925A (en)
TN2012000512A1 (en) Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
TN2012000511A1 (en) Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
MA34818B1 (en) ANTI-PCSK9 ANTIBODIES AND METHODS OF USE
NZ601374A (en) Stabilized antibody-containing liquid formulations
MA34519B1 (en) ANTI-FAP ANTIBODIES AND METHODS OF USE
AR094204A1 (en) COMPOSITIONS FOR ORAL CARE CONTAINING AMINO ACID HALURES
MX352823B (en) Protein formulations containing amino acids.
AR059964A1 (en) METHODS TO REDUCE PROTEIN AGLOMERATION
EP2315833B8 (en) Vectors for delivery of light-sensitive proteins and methods of use
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
EP1740183B8 (en) Novel use for pde5 inhibitors
MA34722B1 (en) METHODS AND COMPOSITIONS FOR IMMUNOTHERAPY OF NEURAL DISEASES
UA104677C2 (en) Urea derivatives and their therapeutic use in the treatment of, inter alia, diseases of the respiratory tract
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
MA28985B1 (en) LOXAPINE ANALOGUES AND METHODS OF USE
CL2012002948A1 (en) Stable aqueous formulation comprising protein at least 5 mg / ml of cd-rap protein and a charged amino acid.
HN2008001859A (en) SALTS OF N-HODROXI-3- {4 - {{{2- (2-METHYL-1H-INDOL-3-IL) ETHYL} METHYL} PHENYL} -2E - 2-PROPENAMIDE.
SG162766A1 (en) Benzooxazole-2-on derivatives as lipase and phospholipase inhibitors
MA34643B1 (en) COMPONENT COMPRISING S- [2 - ([[1- (2-ETHYLBUTYL) -CYCLOHEXYL] -CARBONYL] AMINO) PHENYL] 2-METHYLPROPANETHIOATE AND CROSCARMELLOSIS SODIUM
EA200900780A1 (en) EPOTHILON ANALOGUES MODIFIED IN C12-C13 PROVISIONS AS ANTICATIVE MEDICINES
MY146803A (en) Benzothiazol-2-on derivatives as lipase and phospholipase inhibitors
RS53408B (en) Pharmaceutical composition of ibuprofen for injection
AU316238S (en) Lawning applicator for microbiological cultures
MX2013006031A (en) Liposomal formulation of dalcetrapib.